ACI is excited to announce our upcoming Comprehensive Breast Centers of Excellence conference September 23-25,2015. Don’t miss this opportunity to learn from and network with representatives from organizations nationwide that are prepared to deliver superior service to a growing population.
This year’s conference will highlight and discuss a myriad of topics that are relevant to providing ideal patient care. Topics of interest that will be introduced and discussed are the use of up-to-date methods, treatments and equipment, as well as ways to improve our treatment options in effort to continue combating breast cancer. We will also explore the benefits and impact the Patient Protection and Affordable Care Act. Mastering the latter variables will insure quick, cost efficient, and effective treatment at your Breast Center.
Embrace this opportunity to network and learn from the top oncology executives and administrators as they speak on the development and success of their own managerial models. Learn how to do what it takes to become a Breast Center of Excellence and uncover your center’s true potential. Our conference is focused on exploring the latest developments to increase patient volume, improve outcomes and excel in total patient breast cancer care.
Explore techniques to better equip you cancer center with the latest strategies and advancements in medical technology through real case studies, research findings and organizational models from renowned cancer programs. Register for this exclusive industry conference to learn strategies from the top industry leaders and innovators!
Cleveland Clinic’s Breast Center offers a full array of collaborative services, from initial screenings and diagnosis to innovative treatment and supportive counseling. We realize that each person is unique, so our personalized multidisciplinary team approach ensures that you will receive the care that is best for you.
Cleveland Clinic Breast Centers at Main Campus, Beachwood Family Health Center and Fairview Hospital have been awarded a three-year full accreditation designation by the National Accreditation Program for Breast Centers (NAPBC), a program administered by the American College of Surgeons. Accreditation by the NAPBC is only given to those centers that have voluntarily committed to provide the highest level of quality breast care and that undergo a rigorous evaluation process and review of their performance. A breast center that achieves NAPBC accreditation has demonstrated a firm commitment to offer its patients every significant advantage in their battle against breast disease.
Administrative and Clinical Leaders Representing Community Hospitals, Academic Medical Centers, Health Systems, and Long-Term Care Facilities.
Primary titles include:
Bayer’s Radiology Division is a world-leading diagnostic imaging solutions provider. With the combined power of Bayer’s former Medrad and Diagnostic Imaging units, the Division transforms insight into innovation with the goal of enabling improved patient care and productivity in CT, MRI, PET and interventional studies. Our comprehensive and continually evolving portfolio includes medical devices, contrast media, integrated dose-management software (radiation dose and contrast dose) and equipment service. We offer customer solutions to help healthcare teams meet the challenging needs of today’s radiology environment.
Hologic is a multi-billion dollar global healthcare company with over 5,000 employees. With core business units focused on breast health, GYN surgical, skeletal health and diagnostics, we are the world leader in several key areas of healthcare.
We lead the way in innovative solutions for breast cancer screening, diagnostic and treatment technologies. We revolutionized Pap testing for cervical cancer with our ThinPrep® Pap test, now the most widely used cervical specimen collection product in the world. Procleix® assays, developed and manufactured by Hologic and commercialized by Grifols, increase the safety of the world’s donated blood supply. 79% of the U.S. blood supply is tested with Hologic technologies. Our NovaSure® minimally invasive gynecological procedure offers women a lifetime of freedom from heavy menstrual bleeding via a simple five-minute procedure. Our Horizon™ bone densitometer is the only DXA system that reveals the smallest fractures at the earliest stage – helping to keep patients strong and healthy. And our molecular diagnostic tests identify diseases like HPV, chlamydia, gonorrhea, trichomonas, and HIV – often within days of infection.
As the global market leader in vacuum-assisted breast biopsy, Mammotome offers a wide range of products to help radiologists, surgeons and clinicians around the world accurately diagnose breast disease, such as breast cancer, through minimally invasive procedures. Our extensive product portfolio includes the original Mammotome® Breast Biopsy System, Mammotome revolve® (biopsy system), Mammotome elite® (tetherless biopsy system), Mammotome MammoTest® (stereotactic biopsy table), distribution of Faxitron’s CoreVision™ (core specimen radiography), Neoprobe® Gamma Detection System (GDS), as well as a comprehensive portfolio of biopsy site tissue markers.
Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide. Our strong pipeline of biologics and small molecules, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers. By working collaboratively with academic institutions, individual researchers, cooperative research groups, governments, and licensing partners, Pfizer Oncology strives to cure or control cancer with breakthrough medicines, to deliver the right drug for each patient at the right time.
Myriad Genetics is a leading molecular and companion diagnostics company dedicated to making a difference in patients’ lives through the discovery and commercialization of transformative products that assess a person’s risk of developing disease, aid in a timely and accurate diagnosis, determine the risk of disease progression and recurrence and guide personalized treatment decisions.
After more than 40 years, Faxitron continues to be the brand name in dedicated digital radiography for breast biopsy and lumpectomy specimens at the point of care. Faxitron Bioptics, LLC is the world’s largest and only fully vertically integrated, dedicated cabinet x-ray company. We have over 6,500 installations, with systems in use at the leading hospitals and breast centers around the world. In fact, the Top 10 Cancer Centers in the US all own at least one Faxitron system and 90% having multiple systems.
Genomic Health, a global health company founded in August of 2000 and located in Redwood City, California, is committed to improving the quality of cancer treatment decisions through the research, development and commercialization of genomic-based clinical laboratory services. To that end, the company conducts sophisticated genomic research to develop clinically-validated molecular diagnostics which provide individualized information on response to certain types of therapy, as well as the likelihood of disease recurrence. These diagnostic technologies generate information that healthcare providers and patients can use in making treatment decisions.
The company’s lead product, the Oncotype DX breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease and the Oncotype DX prostate cancer test, which predicts disease aggressiveness in men with low risk disease. Genomic Health has a robust pipeline focused on developing tests to further optimize the treatment of breast, colon and prostate cancers, as well as the treatment of renal cancer. To learn more about Oncotype DX tests, visit: www.OncotypeDX.com and www.mybreastcancertreatment.org and www.myprostatecancertreatment.org
AuntMinnie features the latest news and information about medical imaging and is a comprehensive community website for radiologists and related professionals in the medical imaging industry.
AuntMinnie provides a forum for radiologists, business managers, technologists, members of organized medicine, and industry to meet, transact, research, and collaborate on topics within the field of radiology with the ease and speed that only the Internet can provide.
As “The Trusted Resource for Emerging Technology and Clinical Applications in Medical Imaging and Radiation Oncology,” Imaging Technology News (ITN) showcases the latest, most innovative diagnostic & therapeutic technologies and service solutions. ITN is edited for professionals in radiology/medical imaging, therapeutic radiology, business administration and IT in hospitals, freestanding imaging and radiation oncology centers and purchasing organizations. Features include Comparison Charts, Technology Overviews, Advances In, Business & Economics, Case Studies and more.
Oncology Nurse Advisor (ONA) offers clinical updates and evidence-based guidance to the oncology nurse community online and in print. Daily online articles cover late breaking oncology news, safe handling and administration of chemotherapy drugs, side effect management, and new developments in specific cancers.
ONA also features links to continuing education activities and other resources for nurses and patients, including Q&A sections, the Ask A Pharmacist column, and the ONA Forum, in which oncology nurse experts concisely answer readers’ clinical questions.
Women are powerful.
Nearly two decades ago we were founded on—and continue to be motivated by—the singular mission of moving communities to better health through outreach to women. Why women? They’re powerful. And incredibly influential. In fact, they make 80% of the healthcare choices for their families and loved ones.
We partner with hospitals, healthcare companies, and advocacy groups to reach women. To inspire them to action. With fun and engaging grassroots programs. Programs that are proven to positively impact the health of their communities.